Duke University v. Sandoz Inc.

  1. April 08, 2025

    Fed. Circ. Considers Sandoz's Bid To Undo $39M Patent Loss

    The Federal Circuit on Tuesday grappled with Sandoz's challenge to a $39 million verdict against it in Allergan's eyelash growth drug patent infringement case, with one judge questioning the generic-drug maker's argument that a decade-old decision involving a similar patent forestalls the current case.

  2. April 02, 2025

    5 Fed. Circ. Clashes To Watch This Month

    The Federal Circuit will hear arguments this month in patent cases involving Moderna's COVID-19 vaccine and a blockbuster Johnson & Johnson schizophrenia drug, and the court will itself be the subject of a case at another appeals court as Judge Pauline Newman seeks to end her suspension.

  3. March 29, 2024

    Allergan Scoffs At Sandoz Bid To Undo $39M Patent Loss

    Allergan told the Federal Circuit to reject Sandoz's fight over a $39 million verdict against it for infringing an Allergan eyelash growth drug patent, saying Sandoz's reliance on a 2014 decision involving the same drug misses the decision's central point.

  4. January 17, 2024

    Sandoz Asks Fed. Circ. To Wipe Out Allergan's $39M IP Award

    The Federal Circuit is being asked to weigh in on whether the company behind a popular eyebrow growth drug should have scored a $39 million verdict against Novartis' spun-off generic-drug making arm over a patent "related" to one thrown out by the same appeals court almost a decade ago.